# A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

> **NCT00754988** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 666 (actual)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** Metformin
- **DRUG:** Placebo (matching sitagliptin)
- **DRUG:** Placebo (matching taspoglutide)
- **DRUG:** Sitagliptin
- **DRUG:** Taspoglutide

## Key facts

- **NCT ID:** NCT00754988
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 666 (ACTUAL)
- **Last updated:** 2016-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00754988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00754988, "A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00754988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*